Category - Developments

Developments

Aptinyx begins Phase 2 study of Parkinson’s disease-associated mild cognitive impairment

Aptinyx (NASDAQ:APTX) launched a Phase 2 study of NYX-458 for the treatment of mild cognitive impairment associated with Parkinson’s disease (PD). NYX-458 is an n-methyl-d-aspartate, or NMDA, receptor modulator. The 135...

December 5, 2019

Developments

Ra Pharma doses first patient in Phase 2 immune-mediated necrotizing myopathy study

Ra Pharmaceuticals (NASDAQ:RARX) dosed the first patient in its Phase 2 clinical trial evaluating zilucoplan for the treatment of immune-mediated necrotizing myopathy (IMNM). IMNM is an autoimmune disease characterized...

December 5, 2019

Developments

Hummingbird Bioscience raises $19-million in Series B financing

Closely-held Hummingbird Bioscience raised $19-million in a Series B financing round co-led by Mirae Asset Venture Investment and GNTech Venture Capital. Existing investors Heritas Capital and Seeds Capital also...

December 5, 2019

Developments

Aurinia posts positive Phase 3 voclosporin data in lupus nephritis trial

Aurinia Pharmaceuticals (NASDAQ:AUPH; TSX:AUP) reported positive efficacy and safety results from its AURORA Phase 3 trial of voclosporin, in combination with mycophenolate (MMF) and low-dose corticosteroids, in the...

December 4, 2019

Developments

Aldeyra reports positive topline results from Phase 3 dry eye disease trial

Aldeyra Therapeutics (NASDAQ:ALDX) reported positive topline results from the first part of its adaptive Phase 3 trial of topical ocular reproxalap for the treatment of dry eye disease. Part 1 of the study assessed...

December 3, 2019

Developments

Hepion’s Drs. Foster, Mayo, Ure and Trepanier appointed adjunct professors at UofA

Hepion Pharmaceuticals’ (NASDAQ:HEPA) Drs. Robert Foster, CEO; Daren Ure, CSO; Daniel Trepanier, SVP drug development; and Patrick Mayo, SVP clinical pharmacology have been appointed adjunct professors by the University...

December 3, 2019

Developments

Agenda unveiled for BioTuesdays Pre-JPM Virtual Conference

Healthcare-only investor relations and capital markets advisory firm, Kilmer Lucas, unveiled the lineup for its first annual BioTuesdays Pre-JPM Virtual Conference, beginning at 11:00 am ET on Dec. 10, 2019...

December 3, 2019

Developments

Kane Biotech selected to receive conditional award of up to $3.4 million for DispersinB development

Kane Biotech (TSX-V:KNE) was selected to receive an award of up to about $3.4-million from an unnamed government agency for the continuing clinical development of DispersinB to treat biofilm mediated antimicrobial...

December 3, 2019

Developments

Evofem Biosciences’ Amphora meets primary and secondary endpoints in Phase 2 trial

Evofem Biosciences (NASDAQ:EVFM) announced positive topline results from its Phase 2b trial evaluating Amphora for the prevention of urogenital chlamydia and gonorrhea in women. The study met its primary and secondary...

December 2, 2019

Developments

Phathom Pharma starts Phase 3 erosive esophagitis trial

Phathom Pharmaceuticals (NASDAQ:PHAT) launched its Phase 3 trial of vonoprazan for the healing and healing maintenance of erosive esophagitis (EE). EE is a type of gastroesophageal reflux disease, or GERD, caused by...

December 2, 2019

Category - Developments

Subscribe